ZHU, BIBO

Abstract Tissue-resident memory CD8+ T cells (TRM) share characteristics and core residency gene programs with tumor-infiltrating lymphocytes (TILs). However, the transcriptional, metabolic and epigenetic regulation of TRM and TIL differentiation, maintenance and function are largely undefined. Furthermore, it is unknown whether metabolic and epigenetic manipulations can be employed to promote TRM/TIL functional programs for cancer immunotherapy. Here we report a critical mechanism programming the mitochondrial and epigenetic regulation of TRM/TIL functionality in situ. We find that mouse and human TRM/TIL express the transcription factor BHLHE40 and the BHLHE40-associated gene signature. Bhlhe40 is specifically required for TRM and TIL development and poly-functionality. Local PD-1 signaling inhibits TIL Bhlhe40 expression, and Bhlhe40 is critical for TIL reinvigoration following anti-PD therapy. Mechanistically, Bhlhe40 sustains TRM/TIL mitochondrial fitness for the promotion of a functional epigenetic state. Building on these findings, we also identify an epigenetic and metabolic regimen that promotes TRM/TIL gene signatures associated with tissue residency and poly-functionality through in vitro T cell screening. Strikingly, this regimen empowers the anti-tumor activity of CD8+ T cells and possesses therapeutic potential even at an advanced tumor stage in mouse models. Our results provide mechanistic insights on the local regulation of TRM and TIL function, and offer a viable strategy for developing novel immunotherapeutic means for cancer.

Abstract The role of Bcl6 expression in different immune compartments in regulating anti-tumor immunity is relatively unknown. Previous studies have linked Bcl6 expression in PBMC with poor prognosis in non-small cell lung cancer. We found that high expression of Bcl6 in tumor predicts survival in gastric and ovarian cancers. Using cell type specific conditional knockouts, we were able to investigate the contribution of Bcl6 expression in different lineages in modulating immune response to subcutaneously implanted B16-ova melanoma tumors. Myeloid deficiency of Bcl6 results in decreased tumor growth and metastasis. This is accompanied by enrichment of antigen specific T cells within the tumor. These tumor infiltrating T cells show an increased expression of exhausted markers such as PD-1, Lag-3 and Tim-3. Tumor associated innate cells also upregulate PD-L1. Furthermore, the TILs display an enhanced effector profile measured by robust production of granzyme B, interferon gamma and CCL3 on ex vivo stimulation. This is accompanied by increase in poly-functional CD8 T cells. Our result suggests that Bcl6 expression in the monocyte/macrophage lineage dampens the development of effective anti-tumor immunity and augments immunosuppressive tumor microenvironment. We will elucidate the exact underlying mechanisms and evaluate the translational potential of Bcl6 inhibitors in conjunction with immune checkpoint blockade in the future.